Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0B5UH
|
||||
| Drug Name |
ALX-0761
|
||||
| Drug Type |
Monoclonal antibody
|
||||
| Indication | Psoriasis [ICD9: 696; ICD10:L40] | Phase 1 | [1] | ||
| Company |
Ablynx
|
||||
| Target and Pathway | |||||
| Target(s) | Interleukin-17 | Target Info | Modulator | [2] | |
| Interleukin-17 ligand | Target Info | Modulator | [2] | ||
| KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
| Inflammatory bowel disease (IBD) | |||||
| Rheumatoid arthritishsa04060:Cytokine-cytokine receptor interaction | |||||
| Rheumatoid arthritis | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Interleukin signaling pathway | ||||
| Pathway Interaction Database | IL27-mediated signaling events | ||||
| IL23-mediated signaling events | |||||
| WikiPathways | TCR Signaling Pathway | ||||
| Allograft Rejection | |||||
| IL17 signaling pathwayWP69:TCR Signaling Pathway | |||||
| IL17 signaling pathway | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT02156466) Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects | ||||
| REF 2 | Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. doi: 10.1038/nrd4478. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.